Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Non-Current Assets (2016 - 2026)

Oramed Pharmaceuticals filings provide 15 years of Non-Current Assets readings, the most recent being $97.6 million for Q4 2025.

  • Quarterly Non-Current Assets rose 709.43% to $97.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $97.6 million through Dec 2025, up 709.43% year-over-year, with the annual reading at $97.6 million for FY2025, 709.43% up from the prior year.
  • Non-Current Assets hit $97.6 million in Q4 2025 for Oramed Pharmaceuticals, up from $84.4 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $97.6 million in Q4 2025 and bottomed at $4.2 million in Q1 2021.
  • Average Non-Current Assets over 5 years is $30.8 million, with a median of $27.0 million recorded in 2022.
  • Peak annual rise in Non-Current Assets hit 1193.97% in 2023, while the deepest fall reached 83.87% in 2023.
  • Oramed Pharmaceuticals' Non-Current Assets stood at $30.1 million in 2021, then plummeted by 84.95% to $4.5 million in 2022, then soared by 1178.78% to $58.0 million in 2023, then crashed by 79.2% to $12.1 million in 2024, then skyrocketed by 709.43% to $97.6 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Non-Current Assets are $97.6 million (Q4 2025), $84.4 million (Q3 2025), and $62.7 million (Q2 2025).